66 results on '"Kumada, Hiromitsu"'
Search Results
2. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
3. HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients
4. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma
5. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
6. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis
7. A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis
8. A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma
9. Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection
10. Noninvasive Assessment of Fat and Iron Deposition in the Liver by PDFF and T2* Measurement Using the 6-Point DIXON Method
11. Mo1411 - An Integrated Analysis of the Efficacy of Glecaparevir/Pibrentasvir by Geographical Region
12. Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition
13. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials
14. Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease
15. Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma
16. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
17. The Patient-Related Burden of Pegylated-Interferon-α Therapy and Adverse Events among Patients with Viral Hepatitis C in Japan
18. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b
19. Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus
20. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region
21. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
22. Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay
23. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
24. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
25. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
26. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
27. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
28. Peginterferon Alfa-2a in Japanese HBeAg-Positive Patients is Not Inferior to Conventional Interferon Therapy
29. Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma
30. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients
31. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
32. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay
33. Diabetes Enhances Hepatocarcinogenesis in Noncirrhotic, Interferon-treated Hepatitis C Patients
34. ITPA Polymorphism Affects Ribavirin-Induced Anemia and Outcomes of Therapy—A Genome-Wide Study of Japanese HCV Virus Patients
35. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir
36. Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C
37. A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C
38. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up
39. Viral Elimination Reduces Incidence of Malignant Lymphoma in Patients with Hepatitis C
40. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H
41. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b
42. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels
43. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes
44. A unique amino acid substitution, T126I, in human genotype C of hepatitis B virus S gene and its possible influence on antigenic structural change
45. Long-term Outcome of HBV Carriers with Negative HBe Antigen and Normal Aminotransferase
46. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
47. Long-Term Outcome after Hepatitis B Surface Antigen Seroclearance in Patients with Chronic Hepatitis B
48. Effects of Oral Branched-Chain Amino Acid Granules on Event-Free Survival in Patients With Liver Cirrhosis
49. The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
50. Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis – an open-cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.